journal of hcc

  • A new perspective on the immune escape mechanism in HCC

     · Hepatocellular carcinoma (HCC) is the 6th most common cancer worldwide but has the second highest mortality and thus among the common cancers HCC

  • Hepatoma Research

     · Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome pathogenesis, clinical examination and early diagnosis of hepatoma, complications of hepatoma, and their preventions and treatments, etc. Difficulty and Outcomes of Laparoscopic Liver Resection for HCC in

  • Hepatocellular carcinoma (HCC) beyond sorafenib

    Hepatocellular carcinoma (HCC) is the most common primary liver cancer. HCC is the sixth most common cancer and the second leading cause of cancer-related deaths worldwide . In contrast to most solid cancers, the incidence of HCC and HCC-related deaths have increased over the last several decades in many parts of the world including United States.

  • A hypoxia-related signature for clinically predicting

     · Hepatocellular carcinoma (HCC) accounts for 85% of liver cancers, and the disease burden of HCC is increasing globally [].Although progress on treatment strategies for HCC has been made, the overall 5-year survival rate for HCC patients remains less than 20% [].Nowadays, the research of molecular mechanism based on bioinformatics analysis has become one of the most important tools

  • IMbrave150 Updated overall survival (OS) data from a

     · DOI 10.1200/JCO.2021.39.3_suppl.267 Journal of Clinical Oncologypublished online before print January 22, 2021 IMbrave150 Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

  • Hepatocellular carcinoma in non-cirrhotic liver A

    Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, which in turns accounts for the sixth most common cancer worldwide. Despite being the 6 th most common cancer it is the second leading cause of cancer related deaths. HCC typically arises in the background of c

  • VL/HCC 2020Journal FirstVL/HCC 2020

     · A journal-first presentation will be scheduled in a session with topically-related papers. The journal-first manuscripts are published through the journals and will not be part of the VL/HCC proceedings. The journal-first papers will be listed in the conference program. Journal-First Co-chairs. Brad A. Myers, Carnegie Mellon University, USA

  • The Journal of Commerce

    India may be achieving less-than-desired growth in infrastructure, but the growth in social infrastructure such as education, and health has outstripped GDP growth between and as observed by rating agency CRISIL. Thus, the primary objective of this paper is to relate health and education indicators of human capital, and to

  • Hepatocellular Carcinoma Known and Emerging Risk Factors

    Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer with a high mortality rate. While chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections represent the leading risk factors worldwide, the spreading of metabolic disorders, such as diabetes, obesity and non-alcoholic fatty liver disease (NAFLD) justifies the increasing attention on their oncogenic mechanisms.

  • IMbrave150 Updated overall survival (OS) data from a

     · DOI 10.1200/JCO.2021.39.3_suppl.267 Journal of Clinical Oncologypublished online before print January 22, 2021 IMbrave150 Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

  • Identification of new biomarker for prediction of

     · Researchers sought to develop as well as validate a new biomarker for early prediction of hepatocellular carcinoma (HCC) development in early-stage cirrhosis patients. For this, they analyzed mRNA expression and clinical parameters of GSE63898, GSE89377, GSE15654, GSE14520, and

  • Metabolic heterogeneity of human hepatocellular carcinoma

     · Hepatocellular carcinoma (HCC) represents the fifth most common cancer and the third most common cause of cancer-related deaths in the world []. The incidence of HCC in Europe and the United States is constantly rising, turning HCC into a pivotal threat to general health. Robust therapy resistance and very poor prognosis characterize HCC.

  • Atezolizumab plus Bevacizumab in Unresectable

     · A total of 485 patients received at least one dose of trial treatment (329 received atezolizumab–bevacizumab and 156 received sorafenib) and were included in safety analyses. The median duration

  • VL/HCC 2021Journal-First PresentationsVL/HCC 2021

    Welcome to VL/HCC 2021! From the beginning of the computer age, people have sought easier ways to learn, express, and understand computational ideas. Whether this meant moving from punch cards to textual languages, or command lines to graphical UIs, the quest to make computation easier to express, manipulate, and understand by a broader group of people is an ongoing challenge.

  • Cancers Free Full-Text Characteristics and Lenvatinib

    In hepatocellular carcinoma (HCC), CTNNB-1 mutations, which cause resistance to immune checkpoint inhibitors, are associated with HCC with iso-high intensity in the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) in resectable HCC however, analyses on unresectable HCC are lacking. This study analyzed the prevalence, characteristics, response to

  • Cancers Free Full-Text Characteristics and Lenvatinib

    In hepatocellular carcinoma (HCC), CTNNB-1 mutations, which cause resistance to immune checkpoint inhibitors, are associated with HCC with iso-high intensity in the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) in resectable HCC however, analyses on unresectable HCC are lacking. This study analyzed the prevalence, characteristics, response to

  • Home Page Journal of Hepatology

    Journal of Hepatology, Vol. 66, Issue 5 Published in issue May 2017 Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine Causality or casualty?

  • A novel signature based on microvascular invasion predicts

     · In hepatocellular carcinoma (HCC) patients, microvascular invasion (MVI) is associated with worse outcomes regardless of treatment. No single reliable preoperative factor exists to predict MVI. The aim of the work described here was to develop a new MVI− based mRNA biomarker to differentiate between high and low risk patients. Using The Cancer Genome Atlas (TCGA) database, we collected

  • Hepatocellular Carcinoma (HCC) in a Patient With Hepatitis

     · American Journal of Transplantation Images in TransplantationContinuing Medical Education (CME) Each month, the American Journal of Transplantation will feature Images in Transplantation, a journal-based CME activity. Monthly article is selected to educate participants on current developments in the science and imaging of transplantation.

  • Evidence-Based Management of Hepatocellular Carcinoma

     · Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous randomized controlled trials (RCTs) have aimed at improving outcomes across disease stages. We aimed to analyze the current evidence and identify potential factors influencing response to therapies.

  • Australian recommendations for the management of

     · HCC surveillance should be undertaken in non‐cirrhotic individuals with chronic HBV infection who are at increased risk of HCC. C1. 46 (97.8%) 3. Surveillance for HCC should be undertaken using liver ultrasound every 6 months. B1. 49 (98.0%) 4. Combining α‐fetoprotein testing with liver ultrasound may be considered for HCC surveillance. C2

  • Hepatocellular Carcinoma (HCC) in Egypt A comprehensive

     · Worldwide, hepatocellular carcinoma (HCC) is a universal problem and its epidemiological data showed variation from place to place. Hepatocellular carcinoma (HCC) is the sixth and fourth common cancer in worldwide and Egypt, respectively. Egypt ranks the third and 15th most populous country in Africa and worldwide, respectively. The aim of this review is to compare the status of HCC

  • EASL Clinical Practice Guidelines Management of

     · Journal of Hepatology 2018 vol. 69 j 182–236 q Clinical practice guideline panel Peter R. Galle (chair), Alejandro Forner (EASL governing board representative), Josep M. Llovet, Vincenzo Mazzaferro, Fabio of HCC deaths appears to have increased by about 40% from 1990 to 2004, in contrast to the overall rate of cancer deaths,

  • Staging of hepatocellular carcinoma

     · Okuda staging system was proposed in 1985 based on a study of 850 HCC patients [ 6]. This system is the first to combine tumor size (≤ or > 50% of the entire liver) with the variables of liver function such as ascites (presence and absence), serum albumin (≤ or >

  • Role of 18F-FDG PET-CT in initial staging of

     · Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide. Extrahepatic metastasis from HCC occurs in one third of patients with most common sites being the lungs, lymph nodes, bone, and adrenal glands. Various conventional imaging modalities like ultrasonography, computed tomography, magnetic resonance imaging, and bone scan are used in the diagnosis and staging of HCC.

  • Genipin suppression of growth and metastasis in

     · The signal transducer and activator of transcription-3 (STAT-3) can facilitate cancer progression and metastasis by being constitutively active via various signaling. Abundant evidence has indicated that STAT-3 may be a promising molecular target for cancer treatment. In this study, a dual-luciferase assay-based screening of 537 compounds for STAT-3 inhibitors of hepatocellular carcinoma (HCC

  • Targeted Long-Read Sequencing Reveals Comprehensive

     · Hepatitis B virus (HBV) can integrate into the chromosomes of infected hepatocytes, creating potentially oncogenic lesions that can lead to hepatocellular carcinoma (HCC). However, our current understanding of integrated HBV DNA architecture, burden and transcriptional activity is incomplete due to technical limitations. A combination of genomics approaches was used to describe HBV

  • The threshold of alpha-fetoprotein (AFP) for the diagnosis

     · Objective Hepatocellular carcinoma (HCC) has become a pressing health problem facing the world today due to its high morbidity, high mortality, and late discovery. As a diagnostic criteria of HCC, the exact threshold of Alpha-fetoprotein (AFP) is controversial. Therefore, this study was aimed to systematically estimate the performance of AFP in diagnosing HCC and to clarify its optimal threshold.

  • Rates of cirrhosis and hepatocellular carcinoma in chronic

     · nd justification of HCC surveillance is determined by the rate of HCC development. Our study aims to determine the rates of cirrhosis and HCC in HBV patients in Singapore and hence the appropriateness of HCC surveillance. Materials and methods A total of 673 HBV patients were enrolled between March 2003 and March 2004 and followed up for 10 years with regular surveillance for HCC

  • Autoantibody signature in hepatocellular carcinoma using

     · Alpha-fetoprotein (AFP) is a widely used biomarker for hepatocellular carcinoma (HCC) early detection. However, low sensitivity and false negativity of AFP raise the requirement of more effective early diagnostic approaches for HCC. We employed a three-phase strategy to identify serum autoantibody (AAb) signature for HCC early diagnosis using protein array-based approach.

  • Australian recommendations for the management of

     · Abstract. Introduction Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths both globally and in Australia.Surveillance for HCC in at‐risk populations allows diagnosis at an early stage, when potentially curable. However, most Australians diagnosed with HCC